HIF-1 exerts a double-edged sword regulatory role in hippocampal neuronal PANoptosis of Alzheimer's disease through HK2/VDAC1/NLRP3 axis and RIPK3 signal.

This is bench science in a mouse model, several steps removed from any clinical claim about Alzheimer's disease. The mechanistic detail — semaglutide acting through a GLP-1R-AMPK route to shift HIF-1's dual role — adds to a substantial preclinical literature on GLP-1 receptor agonists in neurodegeneration. Human trial evidence for semaglutide in Alzheimer's remains unsettled, so mechanistic findings like this should be read as target biology, not efficacy data.